Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency

Alzamend Neuro ( (ALZN) ) has issued an announcement.

On March 20, 2026, Alzamend Neuro disclosed that it received a notice from Nasdaq stating its stockholders’ equity of approximately $2.2 million as of January 31, 2026 fell below the $2.5 million minimum required to maintain listing on the Nasdaq Capital Market. The letter did not immediately affect trading of the company’s common stock, which continued under the symbol ALZN, but placed the company on a defined timetable to cure the deficiency.

Alzamend Neuro was given 45 days, until May 4, 2026, to submit a plan to regain compliance and could receive up to 180 days from the March 20 notice, or until September 16, 2026, if Nasdaq accepts its remediation plan. Failure to have its plan accepted, or to restore and maintain compliance within the allowed period or meet other listing standards, could lead to a delisting process, though the company would have the right to appeal and temporarily forestall any suspension while a Nasdaq panel reviews its case.

The most recent analyst rating on (ALZN) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Alzamend Neuro stock, see the ALZN Stock Forecast page.

More about Alzamend Neuro

Alzamend Neuro, Inc. is a publicly traded company listed on the Nasdaq Capital Market under the ticker symbol ALZN. The company reports limited stockholders’ equity and has not generated significant revenue from its core business, highlighting ongoing financial challenges and a need for additional funding to support its operations and evolving business model.

Average Trading Volume: 95,312

Technical Sentiment Signal: Sell

Current Market Cap: $7.19M

See more data about ALZN stock on TipRanks’ Stock Analysis page.